Gefitinib-GEFISA®

• High-quality active pharmaceutical ingredient designed for letrozole-based formulations. • Provided as a highly purified, white crystalline powder with consistent physicochemical properties. • Manufactured under strict cGMP conditions to ensure reliable quality and batch-to-batch reproducibility. • E...

• High-purity active pharmaceutical ingredient engineered for pazopanib-based formulations. • Offered as a fine crystalline powder with robust purity and consistent physicochemical properties. • Produced under rigorous cGMP standards to ensure batch-to-batch reproducibility and quality assurance. • Sub...

• High-quality active pharmaceutical ingredient developed for sunitinib-based formulations. • Provided as a fine crystalline powder with exceptional purity and consistent physicochemical attributes. • Manufactured under strict cGMP conditions to ensure uniform quality and batch-to-batch reproducibility....

• Premium-grade active pharmaceutical ingredient formulated for valganciclovir-based products • Supplied as a finely milled crystalline powder with exceptional purity and consistent quality • Produced under strict cGMP conditions to ensure reproducibility and high manufacturing standards • Extensively ...

• Erlotinib blocks the epidermal growth factor receptor’s tyrosine kinase to suppress tumor cell growth. • Validated efficacy in non-small cell lung cancer (first-line). • Offered in tablet form to facilitate patient-friendly, outpatient treatment. • Underpinned by a wide range of peer-reviewed studies...

• Targeted mechanism that selectively inhibits the BCR-ABL tyrosine kinase to disrupt signaling pathways driving abnormal cell growth in chronic myelogenous leukemia and gastrointestinal stromal tumors (first-line). • Clinically established with robust trials confirming its ability to control disease pro...

• Inhibits multiple receptor tyrosine kinases, including VEGF, PDGF, and c-kit, to reduce tumor angiogenesis and growth. • Demonstrated clinical effectiveness in advanced renal cell carcinoma (second-line) and soft tissue sarcoma (second-line) through robust trials. • Administered orally, offering ...

• Multi-targeted tyrosine kinase inhibitor that blocks VEGF and PDGF receptors to hinder tumor angiogenesis and cell proliferation • Proven efficacy in advanced renal cell carcinoma (second-line), gastrointestinal stromal tumors (first-line), and pancreatic neuroendocrine tumors (second-line) • Administ...

• Fampridine acts by blocking voltage-dependent potassium channels, thereby enhancing conduction in demyelinated nerve fibers. • Robust clinical trials have confirmed its ability to improve walking speed and overall mobility in multiple sclerosis patients. • Delivered in tablet form, ensuring convenient...

• Incorporates into nucleic acids to induce DNA hypomethylation. • Clinically validated for myelodysplastic syndromes and AML. • Flexible administration via subcutaneous injection or IV infusion. • Established safety profile confirmed in rigorous clinical trials. • Demonstrated improvements in surviva...

• Inhibits the 26S proteasome, triggering targeted tumor cell apoptosis. • Clinically indicated for multiple myeloma and mantle cell lymphoma. • Offers flexible IV and subcutaneous administration options. • Demonstrated improvements in survival and quality of life. • Established, well-characterized sa...

• Supports DNA synthesis and repair while mitigating methotrexate toxicity. • Proven efficacy in enhancing fluorouracil therapy for colorectal cancer and serving as methotrexate rescue. • Enhances chemotherapeutic regimens to optimize patient outcomes. • Demonstrated tolerability and manageable adverse...